Form 4: Imunon CMO Granted 12,667 Stock Options

Imunon's Chief Medical Officer, Douglas Vincent Faller, was granted 12,667 stock options with an exercise price of $3.95.

Summary

• Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc. (IMNN), was granted 12,667 stock options.
• The options have an exercise price of $3.95 per share, which represents the closing price of Imunon, Inc. Common Stock on the grant date.
• The grant date and earliest transaction date for these options is January 2, 2026.
• The options vest in a staggered manner: 50% on the date of grant (January 2, 2026), 25% on the one-year anniversary of the grant date, and the remaining 25% on the second-year anniversary of the grant date.
• The expiration date for these stock options is January 2, 2036.
• Following this transaction, Mr. Faller beneficially owns 12,667 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive development for aligning management incentives with shareholder interests, though it is a routine compensation event and not indicative of immediate operational or financial breakthroughs.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• Executive compensation through equity grants is a standard practice to attract and retain key talent.

Future Outlook

The vesting schedule of the stock options over a two-year period indicates a long-term incentive for the Chief Medical Officer, aligning future performance with shareholder value creation.

Industry Context

The grant of stock options to a Chief Medical Officer is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to incentivize leadership and align their interests with the company's long-term success and shareholder returns.

Comparison to Industry Standards

• The structure of this stock option grant, including the vesting schedule and exercise price set at the closing market price, is consistent with typical executive compensation practices observed across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and value creation.
• Employees: May signal stability and commitment from key leadership.

Next Steps

• The options will continue to vest according to the specified schedule on the one-year and two-year anniversaries of the grant date.

Key Dates

Keywords

Imunon, IMNN, Stock Option, Insider Transaction, Executive Compensation, Form 4, Douglas Faller, Chief Medical Officer